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Abstract 
Antimicrobial de-escalation (ADE) is defined as the discontinuation of one or more components of combination 
empirical therapy, and/or the change from a broad-spectrum to a narrower spectrum antimicrobial. It is most com-
monly recommended in the intensive care unit (ICU) patient who is treated with broad-spectrum antibiotics as a 
strategy to reduce antimicrobial pressure of empirical broad-spectrum therapy and prevent antimicrobial resistance, 
yet this has not been convincingly demonstrated in a clinical setting. Even if it appears beneficial, ADE may have some 
unwanted side effects: it has been associated with prolongation of antimicrobial therapy and could inappropriately 
be used as a justification for unrestricted broadness of empirical therapy. Also, exposing a patient to multiple, sequen-
tial antimicrobials could have unwanted effects on the microbiome. For these reasons, ADE has important shortcom-
ings to be promoted as a quality indicator for appropriate antimicrobial use in the ICU. Despite this, ADE clearly has a 
role in the management of infections in the ICU. The most appropriate use of ADE is in patients with microbiologically 
confirmed infections requiring longer antimicrobial therapy. ADE should be used as an integral part of an ICU antimi-
crobial stewardship approach in which it is guided by optimal specimen quality and relevance. Rapid diagnostics may 
further assist in avoiding unnecessary initiation of broad-spectrum therapy, which in turn will decrease the need for 
subsequent ADE.
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Introduction
Antimicrobial de-escalation (ADE) is a strategy to 
decrease the spectrum of the empirical antimicrobial 
regimen a few days into the treatment [1]. Multiple defi-
nitions have been used in the past but there appears to 
be consensus that ADE refers to stopping one or more 
components of combination therapy, changing an antimi-
crobial for another molecule with a narrower spectrum 
or a combination thereof (Fig.  1) [2]. Table  1 provides 
an overview of the terminology commonly used in this 
context. 
ADE was introduced in the intensive care unit (ICU) 
at the beginning of the century with the rationale that it 
may prevent the harm from (extremely) broad-spectrum 
empirical regimens [3]. Those were becoming increas-
ingly necessary due to the emerging and mounting phe-
nomenon of antimicrobial resistance (AMR) [4].
Many studies have looked at ADE in the ICU. Most 
were observational and published from centers with a 
particular interest in antimicrobial stewardship pro-
grams (ASP). ADE appears to be safe, but while improved 
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outcomes are frequently reported, selection bias is prev-
alent: ADE is more frequently used in patients who are 
clinically improving [5]. We should be careful not to infer 
causation between ADE and improved clinical outcomes 
[1].
Regardless of the definition used or the interven-
tion studied, it should be very clear that overall 
antimicrobial consumption is linked to AMR, irrespec-
tive of the class of antibiotics. Decreasing antibiotic 
exposure should, therefore, be the priority of any ASP 
[6].
In this manuscript, we aim to highlight recent 
insights into ADE, its value in ASPs and the practical 
application as well as discuss the controversies and 
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Fig. 1 Schematic overview of the timeline of antimicrobial therapy including antimicrobial de-escalation, with the pivotal and companion 
antimicrobial components of the empirical regimen and most common changes within a short antibiotic course for critically ill patients with an 
infection. ‘Antifungals’ refer to  antimicrobials targeting fungal pathogens, ‘anti-MRSA’ to antimicrobials targeting methicillin-resistant Staphylococcus 
aureus, ‘anti-difficult to treat pathogens’ to antimicrobials targeting resistance in Gram-negative pathogens, ‘atypical/intracellular targeted’ refers to a 
second antibiotic commonly prescribed for community-acquired pneumonia, ‘antitoxin effect’ to antimicrobials administered for the suppression of 
toxin and cytokine production, and ‘synergistic effect’ to  most commonly an aminoglycoside given as combination therapy in patients with septic 
shock
Table 1 Definition of terms
Terms Definition
Adequate antimicrobial therapy Antimicrobial therapy active against the pathogen responsible for infection, administered at the dose, route and 
mode in accordance to best current practices
Broad-spectrum therapy Antimicrobial therapy aimed at covering all relevant pathogens potentially causing the infectious episode
Narrow-spectrum therapy Antibiotic with activity exclusively against one specific pathogen or a more limited group of pathogens
Combination therapy Two or more antibiotics aimed at
1. covering the identified or suspected pathogen(s) with more than one antibiotic to hasten pathogen clearance 
using antimicrobials with different mechanisms of action or
2. broadening antimicrobial spectrum
Ecological impact Collateral effects of the antimicrobials administered to the patient, including downstream effects on the patient’s 
microbiota favouring the acquisition, selection and overgrowth of multidrug-resistant bacteria
Pivotal antibiotic Antibiotic that is central to the regimen, usually a beta-lactam antibiotic for Gram-negative severe infections
Companion antibiotics Antibiotics added to the regimen to broaden the spectrum to pathogens not covered by the pivotal agent. 
Commonly glycopeptides and/or aminoglycosides, which are interrupted most of time after a short exposure 
(3 days)
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pitfalls related to the topic. For an overview of recent 
studies, we refer to the ESICM/ESGCIP position state-
ment on this topic [2].
What do we expect from ADE?
ADE aims to reduce broad-spectrum antimicrobial expo-
sure, and as a result decrease the emergence of AMR, 
without impairing patient outcomes [5]. A randomised 
clinical trial comparing continuation or de-escalation 
of the pivotal or main antimicrobial found a decrease in 
broad-spectrum antimicrobial use in the de-escalation 
group, while the mortality rate was similar in both groups 
[7]. Reducing antimicrobial exposure is essential in any 
ASP, as antimicrobial use has an important impact on the 
gut where overgrowth of organisms resistant to antimi-
crobials significantly impacts the intestinal microbiome.
Inadequate empirical therapy has been associated with 
an increased mortality rate in septic shock [8]. ADE indi-
rectly legitimises the use of broad-spectrum empirical 
therapy, as it suggests that—once the causative pathogen 
has been identified and the susceptibility is known—ther-
apy can be scaled down. Therefore, ADE would limit any 
further harm to the microbiome, inflicted by broad-spec-
trum agents and would thus allow for a broad-spectrum 
empirical safety net as well as for the application of anti-
microbial stewardship principles. Observational studies 
and meta-analyses have suggested improved outcomes 
associated with ADE [9, 10], but as mentioned before, 
any causal effect is not likely to be present.
Finally, as discussed elsewhere, ADE may be associ-
ated with cost saving, since it allows reducing the use of 
expensive antimicrobials for short durations and using 
older and less expensive drugs for the continuation of 
treatment [5].
The dark side of de‑escalation
ADE was welcomed as a remedy to mitigate the effects 
of empirical broad-spectrum agents with the assump-
tion that short courses of those agents have little impact 
on the development of AMR. However, this assumption 
has given us an unwarranted sense of safety that ADE 
would prevent the ecological consequences of extremely 
broad-spectrum empirical antimicrobial treatment regi-
mens. These regimens are often considered lifesaving and 
necessary in patients with severe infections especially in 
the setting of high prevalence of AMR. Recent research, 
however, has clearly shown that AMR appears earlier 
than expected in the course of treatment, probably within 
the first few days [11]. Thus, ADE should not be used as 
an excuse for the indiscriminate prescription of broad-
spectrum antimicrobial regimens.
When analysing the influence of this sense of safety 
that ADE has on our prescribing behaviour, we need to 
consider two other issues. First, although none of the 
involved studies was designed to assess its effect on total 
duration of therapy, ADE has been associated with an 
increase in the total duration of antimicrobial therapy [1]. 
There may be multiple possible explanations for this find-
ing, including potential “errors in counting total days of 
therapy” and the perception that narrow-spectrum anti-
microbials are harmless and can be continued for longer 
periods of time [12]. Second, the risk of using ADE as 
an excuse to continue antimicrobials in the absence of 
infection is likely to cause more harm than stopping all 
antimicrobials alltogether. On one hand, narrower agents 
will still cause the emergence of AMR, and on the other, 
continuing antimicrobials in the absence of infection may 
decrease the quality of diagnostic decision-making [13]. 
Finally, the broad- and narrower spectrum antimicrobials 
may differ in their pharmacokinetics resulting in insuf-
ficient concentrations at the site of infection and PK/PD 
target attainment, often with a disadvantage for narrow-
spectrum antibiotics [14].
ADE is often presented as an effective strategy to 
reduce AMR, but no direct associations were found 
between ADE and ecological impact in ICU patients. In 
an observational comparative study, De Bus et al. did not 
find associations between de-escalation and emergence 
of multidrug-resistant (MDR) pathogens [15]. Similar 
findings were reported in a randomised clinical trial com-
paring ADE and continuation of the pivotal antimicrobial 
[7]. Small but significant differences in carbapenem-
resistant Acinetobacter spp. colonisation were observed 
after carbapenem de-escalation [16]. Large numbers 
of patients are probably required to find a difference in 
terms of AMR, suggesting a limited overall ecological 
impact. In brief, the level of evidence showing that ADE 
reduces AMR is low.
ADE, at least for the pivotal agent, is defined by the 
switch from a broad-spectrum antimicrobial to a nar-
rower spectrum antimicrobial. However, “grading” of 
antimicrobials according to spectrum is not an easy 
task. A French group proposed a six-rank consensual 
classification of beta-lactam  antibiotics. Despite several 
Delphi rounds, no consensus was reached to differenti-
ate piperacillin/tazobactam, ticarcillin/clavulanic acid, 
fourth-generation cephalosporin and antipseudomonal 
third-generation cephalosporin. The group could not find 
an agreement on the delay within which ADE should be 
performed and on whether or not the shortening of anti-
microbial therapy duration should be included in ADE 
definition [17]. In parallel, a group of experts from the US 
developed a numerical score to measure the spectrum of 
antimicrobial regimens [18]. The classification that was 
obtained using a Delphi consensus procedure based on 
clinical scenario’s differed from the one reported by the 
239
French group. Piperacillin–tazobactam was the worst 
ecological antimicrobial for the US group, whereas imi-
penem was selected by the French group. This discrep-
ancy underlines how difficult it is to assess the ecological 
impact of antimicrobials, and thereby to define ADE.
Is two (always) better than one?
ADE implicitly involves the use of more than one antimi-
crobial: either the number of antimicrobials is reduced in 
patients who receive combination antimicrobial therapy 
initially, or patients are administered two different anti-
microbials sequentially. Although we generally assume 
that ADE is beneficial, there may also be downsides to 
the use of multiple antimicrobials, even for short periods 
of time.
First, when one antimicrobial is replaced by another 
with a narrower spectrum, it should be considered that 
two antimicrobials may cause more harm than one. For 
example, when empirical treatment with meropenem 
is switched to levofloxacin, this may be considered as 
narrowing of the spectrum, but that patient is exposed 
to two courses of short duration antimicrobial therapy 
with a different —and potentially—cumulative damaging 
effect on the microbiome. Short exposure to broad-spec-
trum antimicrobials already results in early disruption 
of intestinal microbiome [19]. It has been demonstrated 
that as little as 1 day of exposure to imipenem is enough 
to result in AMR [11]. For each day of additional expo-
sure to cefepime or piperacillin/tazobactam, the risk of 
MDR emergence increases with 8% [20]. Furthermore, 
antibiotics have been found to persist for up to 48  h at 
low concentrations after discontinuation [21] and these 
low concentrations are at high risk for the emergence of 
resistance.
Second, combining antimicrobials in empirical therapy 
aims at broadening the spectrum of therapy, reducing 
AMR or creating synergy between drugs; although this 
was documented in experimental studies, the latter two 
effects were never confirmed in vivo. While the reduced 
number of antimicrobials after ADE may appear advan-
tageous, one should question the true need for multiple 
antimicrobials in the first place [22]. Better risk stratifica-
tion, the use of rapid diagnostic techniques and the use of 
surveillance cultures are all strategies that could avoid the 
use of multiple antimicrobials empirically [23].
Finally, the impact of combining different antibiotic 
classes on the intestinal flora is largely unknown [24]. 
Recent studies have shown differential effects according 
to the antimicrobial activity against anaerobes, with a 
four times higher risk of gut colonisation with ceftriax-
one resistant Gram-negative bacteria after being exposed 
to anti-anaerobe antimicrobials [25]. A better insight into 
the effect of different antimicrobials is needed to under-
stand the dynamics that are relevant in ADE.
The role of ADE in ASP: taking a broader 
perspective
In most practice guidelines for ASP, ADE appears as a 
recommended stewardship objective [26]. In the US, a 
survey showed that prior authorisation for selected anti-
microbials, antimicrobial reviews with prospective audit 
and feedback, and guideline development were common 
strategies in ASPs [27], while ADE was not explicitly 
reported as a major component. In a French survey, reas-
sessment of antimicrobial prescriptions, but not specifi-
cally ADE, appears as a major element of ASP for most 
respondents [28]. In nine Dutch hospitals, ADE was not 
yet included in ASP, although responders disclosed that 
the intervention was required in the future program [29].
Of the two most evidence-based ASP interventions 
(post-prescriptional review and prior authorisation [26]), 
post-prescriptional review (which may include ADE) 
gained some advantage over the latter because of its 
larger effect on reducing antimicrobial use [30]. In the 
light of pitfalls of ADE mentioned before, post-prescrip-
tional review by an expert remains essential for good 
antimicrobial practice. However, reviewing antimicrobial 
use only after prescription may equally stimulate unnec-
essary initial broad-spectrum empirical treatment.
It is becoming increasingly clear that duration of ther-
apy can be reduced to 5–7  days for most infections in 
ICU patients [31], with specific exceptions such as some 
pathogens (e.g. S. aureus), patient conditions (immu-
nosuppression) or inadequacy of source control. This 
development certainly questions the indication for ADE. 
If cultures become available 48–72  h after the start of 
therapy, what is the expected benefit of changing well-
instituted therapy for 2 more days? Apart from the con-
siderations discussed earlier, getting ADE done properly 
in daily practice (collect cultures, correctly interpret cul-
tures, instigate change of therapy in concordance with 
prescribers, prevent a time gap without effective antimi-
crobial therapy, adapting dose due to different PK prop-
erties of new antimicrobial, etc.) can be a challenge with 
little apparent benefit.
However, this does not mean in any way that cultures 
should not be taken. For many reasons other than ADE 
(such as potentially inappropriate therapy, duration of 
therapy, MIC determination, complications, follow-up, 
epidemiology), appropriate sampling remains pivotal to 
ASPs in ICU.
Rapid diagnostics (different molecular technology sep-
sis panels, metagenomics), another component of ASP, 
undoubtedly will change the way we will use antimicrobials 
in the future. For example, an observational retrospective 
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study suggested that the use of a rapid test detecting 
MRSA within the first hour after bronchial sampling was 
associated with a reduction of empirical vancomycin or 
linezolid [23]. An ongoing multicentre randomised clini-
cal trial evaluates the use of a rapid diagnostic test detect-
ing early the presence of ESBL in patients with suspected 
infections to Enterobacteriaceae [32]. Rapid diagnostics 
would also give more opportunities for watchful wait-
ing and not start broad-spectrum antimicrobial therapy, 
thereby eradicating ADE practice in subgroups of patients 
[33]. Especially in patients without shock, this could prob-
ably be done safely. Unfortunately, there are still a lot of 
uncertainties regarding the use of these tests to allow their 
routine use in septic ICU patients.
Individualisation of antimicrobial treatment based 
on risk assessment and rapid diagnostics may be a less 
appealing strategy in institutions with high resistance 
rates. It is certainly easier to avoid carbapenems in hos-
pitals where AMR rates are low. Moreover, rapid diag-
nostic techniques are often unavailable in low- and 
middle-income countries where an already higher resist-
ance burden leads to a vicious circle of increasing AMR 
and indiscriminate broad-spectrum empirical treatment. 
In these settings where control of AMR is most urgently 
needed [34]—in spite of its limitations—ADE may still be 
felt as one of the few options to decrease broad-spectrum 
antimicrobial use. Counterintuitively, promoting ADE 
may cause an increase in broad-spectrum antibiotic use 
as an unexpected side effect in these settings [35].
The risks of using ADE as a performance indicator
ADE has been proposed repeatedly as an important 
objective for ASP in hospitals. It has been selected in a 
RAND-modified Delphi procedure among experts as 1 
of 14 key quality indicators (QI) to measure and improve 
appropriate use in hospital [36] and clinimetric proper-
ties have been tested in a large group of hospitalised 
patients [37, 38]. Furthermore, it has been associated 
with reduced mortality, hospital length of stay and cost 
reduction in a systematic review, although the lack of a 
clear definition hampers interpretation of this association 
[39]. As a result, ADE has become an essential quality 
metric to evaluate the success of an ASP. For measure-
ment purposes, “appropriate ADE” has been opera-
tionalised as the number of patients in whom empirical 
antimicrobials have been changed to a less broad-spec-
trum regimen (numerator) divided by all patients who 
were started on empirical therapy on admission (denomi-
nator). The score of the indicator is expressed as a per-
centage. In routine hospital practice, performance on key 
QIs is regarded as increasingly important as hospitals 
are often publicly and financially punished by healthcare 
authorities or health insurance companies if they do not 
meet expectations. As ASPs are now considered essential 
for the quality and safety of hospital care, it is likely that 
QIs related to ASP will come under increasing scrutiny in 
the following years. A higher percentage of “appropriate 
ADE” will be regarded as one of the elements of a more 
successful implementation of an ASP.
However, due to the ongoing discussion about the defi-
nition of appropriate ADE, it remains extremely difficult 
to judge and compare hospitals on this specific QI: when 
is ADE actually considered appropriate, which are defini-
tions and cut-off points? Here are two examples of how 
misinterpretation and unwanted effects of mandatory 
ADE reporting could play out:
1. If broad-spectrum antimicrobial therapy is pre-
scribed for a patient with nosocomial pneumo-
nia, e.g. with meropenem and vancomycin and it is 
changed by simply stopping vancomycin on day 2, 
this will count as ADE, even if the pivotal antimicro-
bial (meropenem) remains unchanged. This (unde-
sirable) course of events would still be considered 
ADE and add to a higher percentage of hospital-wide 
“appropriate ADE”.
2. On the other side, patients who are prescribed (rela-
tively) narrow-spectrum antimicrobial therapy (e.g. 
starting with flucloxacillin for a suspected S. aureus-
related skin and soft tissue infection) and need not 
be changed once cultures become available, are ‘pun-
ished’ as no ADE has taken place while best medical 
practice has been followed.
In summary, it becomes easy to achieve good QI results 
while performing poor antimicrobial stewardship. Even 
worse, starting narrower spectrum therapy is discour-
aged and broad-spectrum empirical is encouraged (as 
this will increase ADE performance metrics). A high per-
formance on a QI for ADE may only reflect an overuse 
of empirical broad-spectrum antimicrobials. Clearly, the 
opportunities to de-escalate are largely determined by 
empirical therapy and, therefore, using ADE as an iso-
lated quality measure should be discouraged.
Microbiological sample interpretation: not so 
simple
Identifying the pathogen responsible for infection is 
critical for ADE, which relies on an accurate interpreta-
tion of microbiological results in the context of clini-
cal presentation of infection. A crucial necessity is to 
obtain cultures from relevant sites before antibiotics 
are administered, as the absence of cultures or nega-
tive cultures has been associated with non-ADE [1]. 
The challenge and complexity of this process in routine 
practice are often underestimated in recommendations 
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and guidelines. First, all samples are not equal: samples 
obtained from sterile sites have a different role com-
pared to samples obtained from superficial sites: e.g. 
positive blood cultures are more relevant than samples 
collected from skin wound or through a drain. In this 
context, respiratory samples are the most challenging 
to interpret in the absence of quantitative cultures or 
other diagnostic approaches that allow discrimination 
between infection and colonisation. Clearly, defining 
ventilator-associated pneumonia as well as hospital-
acquired pneumonia remains difficult and may be an 
obstacle to ADE. Second, infective pathogens should 
be discriminated from colonising pathogens, in the 
absence of accurate biomarkers. Third, all pathogens 
are not equal: identification of S. aureus is more sig-
nificant than that of coagulase-negative Staphylococci, 
although this should be modulated by the clinical con-
text. In brief, there are some situations in which the 
confidence in a sample and its clinical relevance are 
higher compared to some other situations. Here, the 
resulting strategy will rely strongly on the microbiolog-
ical result.
To resolve this issue, an excellent interaction between 
intensivists, surgeons, radiologists, microbiologists and 
infectious diseases physicians is required. While ADE 
is sometimes conducted in patients in whom no micro-
biological samples were available [1], obtaining samples 
before initiating any antimicrobial treatment should be a 
general rule, and the quality and relevance of these sam-
ples are critical.
In the meantime: de‑escalate or not?
Our purpose is not to exclude ADE as a part of ASP’s, 
and we remain convinced that ADE has great value. As 
discussed above, until the validation and large-scale 
use of rapid diagnostic techniques is a reality, ADE—or 
rather streamlining antimicrobial therapy—will remain 
essential. Based on the microbiological results available 
and clinical course of the patient, we recommend a clini-
cal strategy that integrates ADE while acknowledging the 
inherent limitations of this approach.
The planned duration of antimicrobial therapy is 
also to be considered when antimicrobial therapy is re-
evaluated (Fig.  2). For short courses of antimicrobial 
therapy (5  days or less), continuing the empirical treat-
ment, if appropriate, can avoid sequential use of different 
antimicrobials and thus multiple impacts on the micro-
biome. Another option, which should always be consid-
ered is stopping the antimicrobial treatment. Indeed, 
in patients who are improving, e.g. in whom the SOFA 
score decreased during the first 48–72  h, the need for 
continuing treatment beyond day 3 should be debated for 
a significant number of infections. A seminal randomised 
clinical trial suggested that, in patients with non-severe 
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Fig. 2 Antimicrobial management strategies integrating antimicrobial de-escalation in clinical practice
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pulmonary infiltrate, a course of 3  days of ciprofloxacin 
was as efficient as a prolonged treatment [40]. The fea-
sibility of ultra-short course of antimicrobial treatments 
has been suggested in an observational study compar-
ing 259 patients with ventilator-associated pneumonia 
treated for 1–3  days and 1031 treated for > 3  days, the 
outcomes of two groups being similar [41]. For longer 
courses of antimicrobial therapy (7 days or more), ADE 
should probably be a recommended strategy, particularly 
if high-quality and clinically relevant samples are avail-
able. Its presumed effects on AMR and cost are relevant 
in these conditions. For intermediate-duration antimi-
crobial therapy (5–7  days), decisions should be tailored 
according to institutional ASP recommendations.
Ranking antibiotics according to the local epidemiol-
ogy and available drugs probably is more important than 
trying to obtain an international consensus on how anti-
biotics should be classified.
In patients with confirmed infection and who are 
deteriorating, a single integrated recommendation is 
impossible. In our opinion, the first step is to rule out 
other—infectious and non-infectious—causes of shock. 
The second step is to confirm the adequacy of source 
control and dosing of antimicrobial(s). Only then, the 
empirical antimicrobial treatment can be either main-
tained, escalated, de-escalated or stopped.
In patients with negative cultures, another cause of 
organ dysfunction should be considered. If the mecha-
nism is non-infectious, the antimicrobial treatment 
can be stopped; if another source of infection is found, 
new samples are required, and antimicrobials should be 
adapted to the new clinical picture.
Conclusion
In conclusion, ADE has become more clearly defined 
and understood, but until now, a demonstrable impact 
on AMR is lacking. ADE should not be used as a ‘carte 
blanche’ for the unrestricted use of (very-) broad empiri-
cal antimicrobial therapy and it is important to recognize 
that it may have unexpected and unwanted side effects. 
The impact of ADE on the microbiome needs further 
study while one should consider that sequential exposure 
to two different antimicrobials may not necessarily be 
better than to one. We advocate against the use of ADE 
as a QI in the ICU.
In the meantime, ADE should clearly be regarded as 
an important component of ASPs. When applying ADE, 
planned duration of therapy, as well as sample quality and 
relevance need to be incorporated in the decision-mak-
ing process. Efforts should also be aimed at optimising 
empirical therapy, which may reduce the need for ADE 
later on; this is where rapid diagnostic techniques may 
have an important role.
Author details
1 Department of Critical Care Medicine, Ghent University Hospital, C. Heyman-
slaan 10, 9000 Ghent, Belgium. 2 Department of Intensive Care, Radboudumc, 
Nijmegen, The Netherlands. 3 University Medical Centre Ljubljana, Ljubljana, 
Slovenia. 4 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 
5 Intensive Care Unit, Redcliffe Hospital, Faculty of Medicine, University 
of Queensland, Brisbane, QLD, Australia. 6 Department of Anesthesiology 
and Intensive Care Medicine, Aix Marseille Université, Assistance Publique 
Hôpitaux de Marseille, Hôpital Nord, Marseille, France. 
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 10 September 2019   Accepted: 16 November 2019
Published online: 5 February 2020
References
 1. Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman 
J, Tacey M, Timsit JF, Leone M, Zahar JR, De Waele JJ (2016) A system-
atic review of the definitions, determinants, and clinical outcomes of 
antimicrobial de-escalation in the intensive care unit. Clin Infect Dis 
62:1009–1017. https ://doi.org/10.1093/cid/civ11 99
 2. Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, Roberts 
J, Schouten J, Giamarellou H, Rello J, De Waele J, Shorr A, Leone M, 
Poulakou G, Depuydt P, Garnacho-Montero J (2019) Antimicrobial de-
escalation in critically ill patients: a position statement from a task force of 
the European Society of Intensive Care Medicine (ESICM) and European 
Society of Clinical Microbiology and Infectious Diseases (ESCMID) Criti-
cally Ill Patients Study Group (ESGCIP). Intensive Care Med. https ://doi.
org/10.1007/s0013 4-019-05866 -w
 3. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, Correa H, Diaz 
E, Garnacho J, Llorio M, Rios M, Rodriguez A, Solé-Violán J (2001) Interna-
tional conference for the development of consensus on the diagnosis and 
treatment of ventilator-associated pneumonia. Chest 120:955–970. https ://
doi.org/10.1378/chest .120.3.955
 4. De Waele JJ, Akova M, Antonelli M, Canton R, Carlet J, De Backer D, 
Dimopoulos G, Garnacho-Montero J, Kesecioglu J, Lipman J, Mer M, Paiva 
JA, Poljak M, Roberts JA, Rodriguez Bano J, Timsit JF, Zahar JR, Bassetti M 
(2018) Antimicrobial resistance and antibiotic stewardship programs in 
the ICU: insistence and persistence in the fight against resistance. A posi-
tion statement from ESICM/ESCMID/WAAAR round table on multi-drug 
resistance. Intensive Care Med 44:189–196. https ://doi.org/10.1007/s0013 
4-017-5036-1
 5. Mathieu C, Pastene B, Cassir N, Martin-Loeches I, Leone M (2019) Efficacy 
and safety of antimicrobial de-escalation as a clinical strategy. Expert Rev 
Anti Infect Ther 17:79–88. https ://doi.org/10.1080/14787 210.2019.15612 75
 6. Timsit JF, Bassetti M, Cremer O, Daikos G, de Waele J, Kallil A, Kipnis E, Kollef 
M, Laupland K, Paiva JA, Rodríguez-Baño J, Ruppé É, Salluh J, Taccone FS, 
Weiss E, Barbier F (2019) Rationalizing antimicrobial therapy in the ICU: a 
narrative review. Intensive Care Med 45:172–189. https ://doi.org/10.1007/
s0013 4-019-05520 -5
 7. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanese J, Jaber S, Lepape A, 
Constantin JM, Papazian L, Bruder N, Allaouchiche B, Bezulier K, Antonini F, 
Textoris J, Martin C (2014) De-escalation versus continuation of empiri-
cal antimicrobial treatment in severe sepsis: a multicenter non-blinded 
randomized noninferiority trial. Intensive Care Med 40:1399–1408. https ://
doi.org/10.1007/s0013 4-014-3411-8
 8. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Fernández-
Delgado E, López-Sánchez JM (2015) Adequate antibiotic therapy prior to 
ICU admission in patients with severe sepsis and septic shock reduces hos-
pital mortality. Crit Care 19:302. https ://doi.org/10.1186/s1305 4-015-1000-z
243
 9. Gutiérrez-Pizarraya A, Leone M, Garnacho-Montero J, Martin C, Martin-
Loeches I (2017) Collaborative approach of individual participant data of 
prospective studies of de-escalation in non-immunosuppressed critically 
ill patients with sepsis. Expert Rev Clin Pharmacol 10:457–465. https ://doi.
org/10.1080/17512 433.2017.12935 20
 10. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Corcia-
Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-
Vacaro JA (2014) De-escalation of empirical therapy is associated with 
lower mortality in patients with severe sepsis and septic shock. Intensive 
Care Med 40:32–40. https ://doi.org/10.1007/s0013 4-013-3077-7
 11. Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, 
Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plésiat 
P, Andremont A (2013) Emergence of imipenem-resistant gram-negative 
bacilli in intestinal flora of intensive care patients. Antimicrob Agents 
Chemother 57:1488–1495. https ://doi.org/10.1128/AAC.01823 -12
 12. Sadyrbaeva-Dolgova S, Aznarte-Padial P, Pasquau-Liaño J, Expósito-Ruiz 
M, Calleja Hernández MÁ, Hidalgo-Tenorio C (2019) Clinical outcomes of 
carbapenem de-escalation regardless of microbiological results: a pro-
pensity score analysis. Int J Infect Dis 85:80–87. https ://doi.org/10.1016/j.
ijid.2019.04.034
 13. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi 
E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA TG 
(2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-
associated pneumonia in adults: a randomized trial. JAMA 290:2588–2598. 
https ://doi.org/10.1001/jama.290.19.2588
 14. Carlier M, Roberts JA, Stove V, Verstraete AG, Lipman J, De Waele JJ (2015) 
A simulation study reveals lack of pharmacokinetic/pharmacodynamic 
target attainment in de-escalated antibiotic therapy in critically ill patients. 
Antimicrob Agents Chemother 59:4689–4694. https ://doi.org/10.1128/
AAC.00409 -15
 15. De Bus L, Denys W, Catteeuw J, Gadeyne B, Vermeulen K, Boelens J, Claeys 
G, De Waele JJ, Decruyenaere J, Depuydt PO (2016) Impact of de-escalation 
of beta-lactam antibiotics on the emergence of antibiotic resistance in 
ICU patients: a retrospective observational study. Intensive Care Med 
42:1029–1039. https ://doi.org/10.1007/s0013 4-016-4301-z
 16. Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, Ang B, Lye D, Teng CB 
(2015) Safety and clinical outcomes of carbapenem de-escalation as part 
of an antimicrobial stewardship programme in an ESBL-endemic setting. J 
Antimicrob Chemother 70:1219–1225. https ://doi.org/10.1093/jac/dku47 9
 17. Weiss E, Zahar JR, Lesprit P, Ruppe E, Leone M, Chastre J, Lucet JC, Paugam-
Burtz C, Brun-Buisson C, Timsit JF, De-escalation SG (2015) Elaboration of 
a consensual definition of de-escalation allowing a ranking of β-lactams. 
Clin Microbiol Infect 21:649.e1–649.e10. https ://doi.org/10.1016/j.
cmi.2015.03.013
 18. Madaras-Kelly K, Jones M, Remington R, Hill N, Huttner B, Samore M (2014) 
Development of an antibiotic spectrum score based on veterans affairs 
culture and susceptibility data for the purpose of measuring antibiotic 
de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol 
35:1103–1113. https ://doi.org/10.1086/67763 3
 19. Bhalodi AA, van Engelen TSR, Virk HS, Wiersinga WJ (2019) Impact of antimi-
crobial therapy on the gut microbiome. J Antimicrob Chemother 74:i6–i15. 
https ://doi.org/10.1093/jac/dky53 0
 20. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST (2019) Duration of 
exposure to antipseudomonal β-lactam antibiotics in the critically ill and 
development of new resistance. Pharmacotherapy 39:261–270. https ://doi.
org/10.1002/phar.2201
 21. De Waele J, Van Eeckhout C, Vanhaelewyn P, Carlier M, Verstraete AG, Stove 
V (2019) Persistence of piperacillin concentrations after treatment discon-
tinuation: in cauda venenum[letter]. Intensive Care Med 45(1):130–131
 22. Sjövall F, Perner A, Hylander Møller M (2017) Empirical mono-versus 
combination antibiotic therapy in adult intensive care patients with severe 
sepsis—a systematic review with meta-analysis and trial sequential analy-
sis. J Infect 74:331–344. https ://doi.org/10.1016/j.jinf.2016.11.013
 23. Dureau AF, Duclos G, Antonini F, Boumaza D, Cassir N, Alingrin J, Vigne C, 
Hammad E, Zieleskiewicz L, Leone M (2017) Rapid diagnostic test and use 
of antibiotic against methicillin-resistant Staphylococcus aureus in adult 
intensive care unit. Eur J Clin Microbiol Infect Dis 36:267–272. https ://doi.
org/10.1007/s1009 6-016-2795-5
 24. Woerther PL, Lepeule R, Burdet C, Decousser JW, Ruppé É, Barbier F (2018) 
Carbapenems and alternative β-lactams for the treatment of infections 
due to extended-spectrum β-lactamase-producing Enterobacteriaceae: 
what impact on intestinal colonisation resistance. Int J Antimicrob Agents 
52:762–770. https ://doi.org/10.1016/j.ijant imica g.2018.08.026
 25. Boutrot M, Azougagh K, Guinard J, Boulain T, Barbier F (2019) Antibiot-
ics with activity against intestinal anaerobes and the hazard of acquired 
colonization with ceftriaxone-resistant Gram-negative pathogens in ICU 
patients: a propensity score-based analysis. J Antimicrob Chemother 
74:3095–3103. https ://doi.org/10.1093/jac/dkz27 9
 26. Rennert-May E, Chew DS, Conly J, Guirguis M, Slobodan J, Fryters S, Bresee 
L (2019) Clinical practice guidelines for creating an acute care hospital-
based antimicrobial stewardship program: a systematic review. Am J Infect 
Control 47:979–993. https ://doi.org/10.1016/j.ajic.2019.02.010
 27. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz 
GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma 
PD, Chambers HF (2018) Essential resources and strategies for antibiotic 
stewardship programs in the acute care setting. Clin Infect Dis 67:1168–
1174. https ://doi.org/10.1093/cid/ciy25 5
 28. Delannoy M, Agrinier N, Charmillon A, Degand N, Dellamonica J, Leone 
M, Pulcini C, Novy E (2019) Implementation of antibiotic stewardship 
programmes in French ICUs in 2018: a nationwide cross-sectional survey. J 
Antimicrob Chemother 74:2106–2114. https ://doi.org/10.1093/jac/dkz11 3
 29. van Limburg M, Sinha B, Lo-Ten-Foe JR, van Gemert-Pijnen JE (2014) 
Evaluation of early implementations of antibiotic stewardship program ini-
tiatives in nine Dutch hospitals. Antimicrob Resist Infect Control 3:33. https 
://doi.org/10.1186/2047-2994-3-33
 30. Tamma PD, Avdic E, Keenan JF, Zhao Y, Anand G, Cooper J, Dezube R, Hsu 
S, Cosgrove SE (2017) What is the more effective antibiotic stewardship 
intervention: preprescription authorization or postprescription review 
with feedback. Clin Infect Dis 64:537–543. https ://doi.org/10.1093/cid/
ciw78 0
 31. De Waele JJ, Martin-Loeches I (2018) Optimal duration of antibiotic treat-
ment in Gram-negative infections. Curr Opin Infect Dis 31:606–611. https 
://doi.org/10.1097/QCO.00000 00000 00049 1
 32. Garnier M, Gallah S, Vimont S, Benzerara Y, Labbe V, Constant AL, Siami S, 
Guerot E, Compain F, Mainardi JL, Montil M, Quesnel C, BLUE-CarbA SG 
(2019) Multicentre randomised controlled trial to investigate usefulness of 
the rapid diagnostic βLACTA test performed directly on bacterial cell pel-
lets from respiratory, urinary or blood samples for the early de-escalation 
of carbapenems in septic intensive care unit patients: the BLUE-CarbA 
protocol. BMJ Open 9:e024561. https ://doi.org/10.1136/bmjop en-2018-
02456 1
 33. Denny KJ, De Wale J, Laupland KB, Harris PNA, Lipman J (2019) When not 
to start antibiotics: avoiding antibiotic overuse in the intensive care unit. 
Clin Microbiol Infect. https ://doi.org/10.1016/j.cmi.2019.07.007
 34. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, 
Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar 
JR, Poulakou G (2015) Preventive and therapeutic strategies in critically 
ill patients with highly resistant bacteria. Intensive Care Med 41:776–795. 
https ://doi.org/10.1007/s0013 4-015-3719-z
 35. Leone M, Martin C (2008) How to break the vicious circle of antibiotic 
resistances. Curr Opin Crit Care 14:587–592. https ://doi.org/10.1097/
MCC.0b013 e3283 0f1de b
 36. van den Bosch CM, Hulscher ME, Natsch S, Gyssens IC, Prins JM, Geerlings 
SE, Dutch SQIEP (2014) Development of quality indicators for antimicro-
bial treatment in adults with sepsis. BMC Infect Dis 14:345. https ://doi.
org/10.1186/1471-2334-14-345
 37. van den Bosch CM, Geerlings SE, Natsch S, Prins JM, Hulscher ME (2015) 
Quality indicators to measure appropriate antibiotic use in hospitalized 
adults. Clin Infect Dis 60:281–291. https ://doi.org/10.1093/cid/ciu74 7
 38. van den Bosch CM, Hulscher ME, Natsch S, Wille J, Prins JM, Geerlings 
SE (2016) Applicability of generic quality indicators for appropriate 
antibiotic use in daily hospital practice: a cross-sectional point-prevalence 
multicenter study. Clin Microbiol Infect 22:888.e1–888.e9. https ://doi.
org/10.1016/j.cmi.2016.07.011
 39. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek 
HWPM, van der Linden PD, Natsch S, Hertogh CMPM, Wolfs TFW, Schouten 
JA, Kullberg BJ, Prins JM (2016) Current evidence on hospital antimicrobial 
stewardship objectives: a systematic review and meta-analysis. Lancet 
Infect Dis 16:847–856. https ://doi.org/10.1016/S1473 -3099(16)00065 -7
244
 40. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course 
empiric antibiotic therapy for patients with pulmonary infiltrates in the 
intensive care unit. A proposed solution for indiscriminate antibiotic pre-
scription. Am J Respir Crit Care Med 162:505–511. https ://doi.org/10.1164/
ajrcc m.162.2.99090 95
 41. Klompas M, Li L, Menchaca JT, Gruber S, Centers FDCAPEP (2017) Ultra-
short-course antibiotics for patients with suspected ventilator-associ-
ated pneumonia but minimal and stable ventilator settings. Clin Infect 
Dis 64:870–876. https ://doi.org/10.1093/cid/ciw87 0
